Evidence map›Paper›PMID 42197063›Full record

ReviewNutrients2026

Harnessing Botanical Extracts for Asthma Therapy: A Scoping Review of Molecular Mechanisms and the Strategic Utility of Experimental Models (2005-2025).

Jae-Won Lee, Chang Hyeon Jeon, Soo-Jin Park, Hee Jae Lee, Hyung Won Ryu, Su Ui Lee

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jae-Won LeeNatural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea.ORCID 0000-0003-0438-6732
Chang Hyeon JeonNatural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea.
Soo-Jin ParkNatural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea.ORCID 0000-0002-9304-4840
Hee Jae LeeDepartment of Pharmacology, College of Medicine, Kangwon National University, Chuncheon 24341, Republic of Korea.
Hyung Won RyuNatural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea.ORCID 0000-0001-5291-3942
Su Ui LeeImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.ORCID 0000-0002-6455-5414

Funding

Korea Research Institute of Bioscience and Biotechnology KGM1202612Ministry of Agriculture, Food and Rural Affairs RS-2025-02303805
6 · The paper itself

Abstract

Asthma represents a chronic inflammatory condition of the respiratory tract, where long-term bronchial inflammation serves as a primary driver of progressive airway remodeling. This complex pathology emerges from the intricate synergy between host genetic susceptibility and diverse environmental triggers, ultimately impairing pulmonary function. At the cellular level, asthmatic responses are orchestrated by a dynamic crosstalk among various immune and structural populations, including airway epithelial cells, T-lymphocytes, eosinophils, and mast cells, which collectively perpetuate the inflammatory milieu. Although inhaled corticosteroids are the conventional cornerstone of therapy, their clinical application is frequently hindered by potential systemic toxicity and the emergence of steroid-resistant phenotypes. Consequently, botanical extracts derived from both aerial and underground plant organs have gained attention as versatile multi-target candidates capable of modulating the multifaceted pathophysiological networks of asthma. This scoping review critically synthesizes the pharmacological efficacy of these plant-based interventions in regulating pivotal signaling cascades, such as MAPK, NF-κB, STAT3/6, and GATA3. Based on a systematic literature search covering the period from 2005 to 2025, this study provides a focused quantitative analysis of preclinical literature from the last decade (2016-2025) to evaluate the in vitro and in vivo models employed to validate these therapeutic effects. The assessment reveals that the vast majority of current research continues to rely on crude botanical preparations, with only a limited subset of studies utilizing enriched fractions or fully characterized isolated compounds. This predominance of unrefined extracts underscores a significant gap in chemical standardization and highlights the necessity for more rigorous mechanistic validation. Ultimately, this paper outlines strategic pathways for translating preclinical findings into clinical practice, offering a robust framework for the development of standardized plant-derived interventions in asthma management.

Indexed as

Anti-Asthmatic AgentsAsthmaPhytotherapyPlant ExtractsAnimalsDisease Models, AnimalHumansSignal TransductionAnti-Asthmatic AgentsPlant Extractsairway inflammationasthmabioactive compoundsmolecular mechanismsplant extractstranslational utility

Identifiers

PMID42197063
PMCPMC13209799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.